JP2018504892A5 - - Google Patents

Download PDF

Info

Publication number
JP2018504892A5
JP2018504892A5 JP2017531209A JP2017531209A JP2018504892A5 JP 2018504892 A5 JP2018504892 A5 JP 2018504892A5 JP 2017531209 A JP2017531209 A JP 2017531209A JP 2017531209 A JP2017531209 A JP 2017531209A JP 2018504892 A5 JP2018504892 A5 JP 2018504892A5
Authority
JP
Japan
Prior art keywords
classifier score
breast cancer
subject
luminal
basal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017531209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504892A (ja
JP6735277B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/064500 external-priority patent/WO2016094408A1/en
Publication of JP2018504892A publication Critical patent/JP2018504892A/ja
Publication of JP2018504892A5 publication Critical patent/JP2018504892A5/ja
Application granted granted Critical
Publication of JP6735277B2 publication Critical patent/JP6735277B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017531209A 2014-12-12 2015-12-08 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法 Expired - Fee Related JP6735277B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462091195P 2014-12-12 2014-12-12
US62/091,195 2014-12-12
US201562142504P 2015-04-03 2015-04-03
US62/142,504 2015-04-03
US201562167110P 2015-05-27 2015-05-27
US62/167,110 2015-05-27
PCT/US2015/064500 WO2016094408A1 (en) 2014-12-12 2015-12-08 Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Publications (3)

Publication Number Publication Date
JP2018504892A JP2018504892A (ja) 2018-02-22
JP2018504892A5 true JP2018504892A5 (https=) 2019-01-24
JP6735277B2 JP6735277B2 (ja) 2020-08-05

Family

ID=55273509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017531209A Expired - Fee Related JP6735277B2 (ja) 2014-12-12 2015-12-08 乳癌療法剤に対する反応を予測するための方法および乳癌の処置の方法

Country Status (15)

Country Link
US (3) US10196693B2 (https=)
EP (2) EP3604556A1 (https=)
JP (1) JP6735277B2 (https=)
KR (1) KR20170095306A (https=)
CN (1) CN107109488A (https=)
AU (1) AU2015360767A1 (https=)
BR (1) BR112017012142A2 (https=)
CA (1) CA2970469A1 (https=)
ES (1) ES2748005T3 (https=)
IL (1) IL252587A0 (https=)
MX (1) MX2017007707A (https=)
RU (1) RU2017120330A (https=)
SG (1) SG11201704425TA (https=)
WO (1) WO2016094408A1 (https=)
ZA (1) ZA201703904B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20140243211A1 (en) 2013-02-28 2014-08-28 Indiana University Research & Technology Corporation Blood biomarkers for suicidality
CN107109488A (zh) * 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法
WO2016201299A1 (en) 2015-06-12 2016-12-15 Indiana University Research & Technology Corporation Predicting suicidality using a combined genomic and clinical risk assessment
KR101966493B1 (ko) * 2016-06-27 2019-04-05 국립암센터 삼중음성유방암 예후 예측용 바이오마커
KR101896558B1 (ko) * 2016-11-21 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
CN110573958A (zh) * 2017-04-26 2019-12-13 日本电信电话株式会社 N×n光开关
EP3635130A4 (en) 2017-05-12 2021-06-09 Indiana University Research and Technology Corporation Precision medicine for treating and preventing suicidality
RU2648523C1 (ru) * 2017-05-22 2018-03-26 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр" Российской академии наук ("Томский НИМЦ") Способ прогнозирования исхода заболевания у больных люминальным в и трижды негативным раком молочной железы у пациенток, не получавших в неоадъювантном режиме химио- или гормонотерапию
KR102542275B1 (ko) * 2018-05-14 2023-06-12 하이노바 파마슈티컬스 인코포레이티드 Hc-1119 제제 및 그 제조방법 및 용도
WO2020001473A1 (zh) * 2018-06-28 2020-01-02 复旦大学 小核仁核糖核酸snord33作为生物标记物用于制备检测试剂盒中的用途
CN109735625A (zh) * 2019-03-18 2019-05-10 马榕 乳头溢液在检测肿瘤相关基因中的应用
CN114334000B (zh) * 2021-12-28 2025-07-25 上海中医药大学 基于转录组图谱的组合药物生成方法、系统及存储介质
US20260043086A1 (en) * 2022-08-06 2026-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Predictive biomarker in avastin in colon cancer

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6937713B1 (en) 1999-12-30 2005-08-30 At&T Corp. IP call forward profile
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20070192880A1 (en) 2003-10-03 2007-08-16 University Of Rochester Horming response element binding transregulators
US20070059720A9 (en) 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
EP2620432A3 (en) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoin compounds
US7732491B2 (en) * 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
ES2457534T3 (es) 2008-05-30 2014-04-28 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
SG173837A1 (en) 2009-02-24 2011-09-29 Medivation Prostate Therapeutics Inc Specific diarylhydantoin and diarylthiohydantoin compounds
US8710086B2 (en) 2009-04-09 2014-04-29 Medivation Technologies, Inc. Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof
WO2010125117A2 (en) 2009-04-29 2010-11-04 Ralph Wirtz A method to assess prognosis and to predict therapeutic success in cancer by determining hormone receptor expression levels
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
JP2013504064A (ja) 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート 循環腫瘍細胞を分類する方法
EP2485804A4 (en) 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
EP2685988A4 (en) * 2011-03-15 2014-08-20 Univ North Carolina Methods of treating breast cancer with anthracycline therapy
US8781912B2 (en) 2011-03-15 2014-07-15 Opera Solutions, Llc Computer-based method and computer program product for setting floor prices for items sold at auction
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
JP6144695B2 (ja) 2011-11-30 2017-06-07 ユニバーシティー オブ ノースカロライナ アット チャペル ヒル タキサン療法を用いて乳癌を処置する方法
ES2696202T3 (es) 2012-08-23 2019-01-14 Univ Colorado Regents Método para determinar el tratamiento de cáncer de mama
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) * 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
CN107109488A (zh) 2014-12-12 2017-08-29 麦迪韦逊前列腺治疗股份有限公司 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法

Similar Documents

Publication Publication Date Title
JP2018504892A5 (https=)
RU2017120330A (ru) Способ прогнозирования ответа на терапевтические агенты для лечения рака молочной железы и способ лечения рака молочной железы
KR20160006668A (ko) 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물
JP2019518741A (ja) Ｈｄａｃ阻害剤とｐｄ−ｌ１阻害剤との組み合わせ療法
JP2016540767A (ja) 局所進行性又は転移性エストロゲン受容体陽性乳がんの治療のためのエストロゲン受容体調節因子
WO2012167028A2 (en) Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition
Lu et al. Cancer metastasis, a clinical dilemma for therapeutics
Cheong et al. Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance
CN107405316A (zh) 用于治疗原发性激素耐受性子宫内膜癌和乳腺癌的方法
JP2018513155A (ja) セリバンツマブを用いた併用療法
Saadh et al. Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy
JP2020517739A (ja) リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ
RU2624370C1 (ru) Способ лечения люминального подтипа рака молочной железы N1 в постменопаузальном периоде
CN112218627A (zh) 前药及其在医学上的应用
Tian et al. 1014P Resistance landscape to almonertinib in EGFR-mutated NSCLC
Kaushik et al. Overview of Chemoresistance in Cancerous Cells
WO2018144597A1 (en) Methods of sensitizing cancer cells to immune cell killing
Wasi Skeletal Effects of Combined Yoda1 and Tibial Loading in Aged Mice Bearing Metastatic Breast Cancer and Undergoing Chemotherapy
O'Byrne et al. 1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer
RU2706029C1 (ru) Способ лечения люминального подтипа рака молочной железы
JP2020500543A5 (https=)
Mitra et al. 121P Calcite-driven cytotoxicity in glioblastoma cells: A promising therapeutic approach
Ge et al. Emodin sensitizes ovarian cancer cells to carboplatin through suppression of mitochondrial respiration
Ahmed et al. 128P Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Li et al. Effect of DDX46 targeted suppression on the proliferation and apoptosis of ovarian cancer cell line SK-OV-3